7.52
-0.15(-1.96%)
Currency In USD
Previous Close | 7.67 |
Open | 7.85 |
Day High | 7.85 |
Day Low | 7.51 |
52-Week High | 896 |
52-Week Low | 6.71 |
Volume | 19,721 |
Average Volume | 1.1M |
Market Cap | 9.06M |
PE | -0.01 |
EPS | -502.73 |
Moving Average 50 Days | 8.45 |
Moving Average 200 Days | 66.97 |
Change | -0.15 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0.38 as of August 31, 2025 at a share price of $7.52. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0.37 as of August 31, 2025 at a share price of $7.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
GlobeNewswire Inc.
Jul 31, 2025 12:10 PM GMT
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutic
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
GlobeNewswire Inc.
Jun 23, 2025 12:15 PM GMT
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L wi
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Jun 17, 2025 12:15 PM GMT
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutic